Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics, Inc. (NASDAQ: FATE) is a transformative approach to cellular immunotherapy through its proprietary induced pluripotent stem cell (iPSC) platform. This page serves as the definitive source for verified news and press releases directly from the clinical-stage biopharmaceutical leader.
Access real-time updates on clinical trial progress, regulatory milestones, and strategic partnerships driving next-generation cancer treatments and autoimmune therapies. Investors will find essential announcements including quarterly earnings, product pipeline advancements, and manufacturing developments related to off-the-shelf CAR T-cell and NK-cell programs.
Our curated collection includes filings with the SEC, peer-reviewed research publications, and updates on multiplexed-engineered iPSC lines. Stay informed about the company’s pioneering work in creating pharmaceutical-grade cell products that aim to overcome limitations of traditional donor-derived therapies.
Bookmark this page for streamlined tracking of Fate Therapeutics’ progress in immuno-oncology and regenerative medicine. Check regularly for authoritative updates on clinical data readouts, collaboration expansions, and technological breakthroughs in stem cell biology.
Fate Therapeutics presented positive clinical data from its Phase 1 study of FT516 at the 63rd ASH Annual Meeting. The investigational NK cell therapy showed promising results with 6 of 10 CAR T-naïve patients continuing to respond at a median follow-up of 9.1 months. Additionally, 3 of 8 previously treated patients achieved a complete response. FT516 was well-tolerated, with no major safety concerns reported. The FDA granted FT516 RMAT designation, promoting expedited development for relapsed/refractory DLBCL. The company initiated dose-expansion cohorts at 900 million cells per dose, aiming to enroll diverse patient populations.
Fate Therapeutics, Inc. (NASDAQ: FATE) announced a virtual event titled “B-cell Lymphoma Franchise Update” on December 14, 2021, at 8:00 AM ET. The event will present interim Phase 1 clinical data for the FT516 and FT596 programs targeting relapsed/refractory B-cell lymphomas. Access to the live webcast will be available on the company's website, with an archive posted two hours post-event. Fate Therapeutics specializes in programmed cellular immunotherapies leveraging its induced pluripotent stem cell (iPSC) platform, holding over 350 patents to support its innovative treatments.
Fate Therapeutics, a clinical-stage biopharmaceutical firm focused on cellular immunotherapies for cancer, will present at several upcoming investor conferences. Notable events include the Jefferies London Healthcare Conference on November 18, 2021, the Piper Sandler 33rd Annual Healthcare Conference on November 23, 2021, and the Evercore ISI HealthCONx Conference on November 30, 2021. These presentations will be available on demand, and a live webcast will be accessible via the company's website. Fate Therapeutics aims to enhance cancer treatments with innovative cell therapies.
Fate Therapeutics announces its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting with a selected abstract showcasing preclinical data from its FT538 and FT573 programs. Key findings indicate FT538's efficacy against glioblastoma cells and its combination with an NK cell engager targeting B7-H3. A live audio webcast will take place on November 15, 2021, highlighting its emerging iPSC-derived NK cell pipeline. The company emphasizes its innovative iPSC platform's potential to enhance cancer treatment through engineered cell therapies.
Fate Therapeutics announced the enrollment of patients in Phase 1 clinical studies for FT538 and FT576 targeting relapsed/refractory multiple myeloma. Interim data from FT596 and FT516 for relapsed/refractory lymphoma show promising results with 71% and 73% objective response rates (ORR) respectively. Both FT596 and FT516 demonstrate differentiated safety profiles with low-grade adverse events. Financial results reveal total revenue of $14.2 million for Q3 2021, alongside R&D expenses of $53.1 million and cash reserves of $803.6 million as of September 30, 2021.
Fate Therapeutics (NASDAQ: FATE) announced a conference call for November 4, 2021, at 5:00 p.m. ET to discuss its third quarter 2021 financial results and corporate updates. Shareholders can join the call by dialing (877) 303-6235 domestically or (631) 291-4837 internationally, using conference ID 9459084. The live audio webcast will be available under the Events section of the company's website. Fate Therapeutics focuses on developing first-in-class cellular immunotherapies for cancer, leveraging its proprietary induced pluripotent stem cell technology.
Tentarix Biotherapeutics LP has secured a $50 million Series A investment, co-led by Versant Ventures and Samsara BioCapital. This funding will accelerate the development of its advanced biotherapeutic platform, designed for targeted, multifunctional therapies aimed at oncology and autoimmune diseases. The company focuses on creating antibody-based products that selectively activate immune responses, reducing adverse effects. Tentarix's lead program targets the IL2R gamma and beta receptors, showcasing potential breakthroughs in cell-specific therapies.
Fate Therapeutics, Inc. (NASDAQ: FATE) announced the acceptance of one oral and four poster presentations for its induced pluripotent stem cell (iPSC) platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 10-14, 2021. The oral presentation will focus on preclinical data for FT536, a CAR NK cell candidate targeting MICA/B proteins. Additionally, poster presentations will cover advancements in CAR T cell therapies for solid tumors. Fate plans to submit an IND application for FT536 in Q4 2021.
Fate Therapeutics announces the publication of preclinical data on FT538, its engineered iPSC-derived NK cell product candidate, showcasing enhanced anti-tumor activity compared to traditional NK cells. The data reveal that FT538 demonstrates significant functional persistence and superior serial killing capability. Key innovations include the knockout of CD38 and the introduction of an IL-15/IL-15R fusion protein. FT538 is currently undergoing Phase 1 trials for treating acute myeloid leukemia and multiple myeloma, positioning it as a promising off-the-shelf therapy in cancer immunotherapy.
FAQ
What is the current stock price of Fate Therapeutic (FATE)?
What is the market cap of Fate Therapeutic (FATE)?
